In Profession news

Follow this topic

Bookmark

Record learning outcomes

A pharmacist who authorised prescriptions for Mounjaro without requesting face-to-face consultations while working at an unregulated aesthetics clinic for two weeks last year has received a warning from the General Pharmaceutical Council’s investigating committee (IC).

Independent prescriber Aroosa Malik was reprimanded by the IC over her conduct while working at London company Skin & Drip between April 28 and May 12 in 2025.

It was found that Ms Malik had prescribed “high-risk injectable weight loss medication” without requesting face-to-face consultations, contacting patients directly or obtaining details relating to their overall health to assess their need for ongoing treatment. 

She “relied principally” on information provided in the form of screenshots by a “non-clinical colleague” at the unregulated clinic rather than access patient records herself, said the IC, adding that she failed to contact patients’ GPs or obtain “independent confirmation” of their “weight loss journey”.

The IC stated: “Ms Malik did not take proper consideration of the risks associated with prescribing large quantities of weight loss medication to patients who may be vulnerable or at risk of medication abuse or dependence and ensure appropriate safety netting for these patients was in place.”

There were also issues around the details recorded on the prescriptions, which “did not accurately reflect the entity issuing the prescriptions nor provide sufficient contact details for the prescriber”.

She was found to have breached professional standards relating to person-centred care, working in partnership with others, using professional judgment and demonstrating leadership.

The IC took note of Ms Malik’s insight and remorse, in addition to the explanation she provided for her conduct and the CPD she has since completed.

She was warned that prescribing decisions taken without a face-to-face consultation “should include independent verification of information provided and should only be offered in regulated settings” and reminded of the “robust systems and checks” that are needed to prevent harm when prescribing medicines that are high-risk and require ongoing monitoring.

The warning will appear on Ms Malik’s registry entry for 12 months.